[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration-Reference-Cited by-同舟云学术

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration

Published:2017-12-26 Issue:5 Volume:9 Page:6062-6074
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Booth Laurence¹,Roberts Jane L.¹,Rais Rumeesa¹,Kirkwood John²,Avogadri-Connors Francesca³,Cutler Richard E.³,Lalani Alshad S.³,Poklepovic Andrew⁴,Dent Paul¹

Affiliation:

1. Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA

2. University of Pittsburgh Cancer Institute Melanoma and Skin Cancer Program, Hillman Cancer Research Pavilion Laboratory L1.32c, Pittsburgh, PA 15232, USA

3. Puma Biotechnology Inc., Los Angeles, CA 90024, USA

4. Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells;Anti-Cancer Drugs;2023-10-16

2. Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells;Anti-Cancer Drugs;2023-08-31

3. Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours;European Medical Journal;2022-09-20

4. Neratinib kills B‐RAF V600E melanoma via ROS‐dependent autophagosome formation and death receptor signaling;Pigment Cell & Melanoma Research;2021-09-04

5. Cell Signaling and Translational Developmental Therapeutics;Reference Module in Biomedical Sciences;2021